Peptide Half-Life Guide
A comprehensive pharmacokinetics reference covering half-life fundamentals, modification strategies, steady-state concepts, and a complete peptide duration reference table.
What Is Half-Life in Pharmacokinetics?
In pharmacokinetics, half-life (t½) refers to the time required for the plasma concentration of a substance to decrease by exactly 50% from its peak value. It is one of the most fundamental parameters used to characterize how the body processes a drug or peptide, and it directly governs critical research decisions including dosing frequency, washout periods, and the time needed to reach stable circulating levels.
For peptides specifically, half-life is a particularly important consideration because native (unmodified) peptides tend to have extremely short half-lives, often measured in minutes rather than hours. This is because the body is equipped with highly efficient enzymatic machinery designed to rapidly degrade signaling peptides after they have fulfilled their physiological role. Enzymes like dipeptidyl peptidase-4 (DPP-4), neutral endopeptidase (NEP), angiotensin-converting enzyme (ACE), and numerous other proteases cleave peptide bonds at specific recognition sites, rendering the peptide fragments biologically inactive.
Beyond enzymatic degradation, peptides are also rapidly cleared by the kidneys through glomerular filtration. Most unmodified peptides have molecular weights well below the ~60 kDa renal filtration threshold, meaning they pass freely through the glomerular capillaries and are excreted in urine. The combination of rapid proteolysis and efficient renal clearance gives native peptides half-lives ranging from just 2 minutes (native GLP-1) to about 10 minutes (native ghrelin).
Understanding the mathematical relationship behind half-life is essential for designing research protocols. The elimination of most peptides follows first-order kinetics, meaning that a constant fractionof the peptide is eliminated per unit time, regardless of concentration. This gives rise to an exponential decay curve: after one half-life, 50% remains; after two half-lives, 25%; after three, 12.5%; after four, 6.25%; and after five half-lives, only about 3.125% of the original dose remains. This “rule of five” is the basis for both washout period calculations and steady-state predictions.
Why Half-Life Matters for Dosing Frequency
Half-life is the primary determinant of dosing frequency in any research protocol. A peptide with a 2-minute half-life, such as native GLP-1, would require continuous intravenous infusion to maintain any meaningful plasma concentration. This is precisely why pharmaceutical research has invested heavily in developing long-acting analogs: semaglutide, with its ~7-day half-life, achieves with a single weekly injection what native GLP-1 cannot accomplish even with continuous delivery.
The relationship between half-life and dosing interval also determines the degree of peak-to-trough fluctuation in plasma concentrations. When a peptide is dosed at intervals equal to its half-life, the trough concentration (just before the next dose) will be approximately 50% of the peak concentration. Dosing more frequently reduces this fluctuation, producing more stable plasma levels, while less frequent dosing increases the swing between peak and trough.
For research peptides that mimic pulsatile hormonal signaling, such as growth hormone secretagogues (ipamorelin, GHRP-2, GHRP-6), a shorter half-life is actually desirable. The natural secretion pattern of growth hormone involves discrete pulses separated by periods of low basal secretion. A short-acting secretagogue can reproduce this pulsatile pattern, whereas an ultra-long-acting agent would produce continuous stimulation that may desensitize receptors over time. This illustrates an important principle: longer half-life is not always better; the optimal half-life depends on the biological context and research objectives.
For further context on how route of administration interacts with half-life to determine effective drug exposure, see our Bioavailability Calculator and bioavailability glossary entry.
Factors Affecting Peptide Half-Life
Molecular Weight and Size
Molecular weight is a primary determinant of renal clearance. Peptides below ~5-7 kDa are rapidly filtered by the kidneys. Larger peptides and proteins above ~60 kDa are largely retained in circulation. This is why strategies that increase the effective hydrodynamic radius of a peptide, such as PEGylation or Fc fusion, dramatically extend half-life by pushing the molecule above the renal filtration cutoff.
PEGylation
PEGylation involves the covalent attachment of polyethylene glycol (PEG) polymer chains to a peptide. PEG is a hydrophilic, biocompatible polymer that increases the hydrodynamic radius of the conjugate far beyond what the molecular weight alone would predict. A 40 kDa PEG chain, for instance, creates an effective hydrodynamic radius comparable to a ~300 kDa protein, which virtually eliminates renal clearance. Additionally, the PEG “shield” sterically hinders protease access to the peptide backbone, reducing enzymatic degradation. The trade-off is that PEGylation can reduce receptor binding affinity if the PEG is attached near the pharmacophore, and there are emerging concerns about anti-PEG antibodies with repeated dosing.
Fatty Acid Acylation (Lipidation)
Fatty acid acylation, exemplified by semaglutide’s C18 fatty diacid chain, promotes reversible binding to serum albumin. Since albumin has a half-life of approximately 19 days and is efficiently recycled by the neonatal Fc receptor (FcRn) pathway, peptides that “hitchhike” on albumin benefit from dramatically reduced clearance. The free fraction of the peptide maintains pharmacological activity, while the albumin-bound fraction serves as a circulating reservoir. This approach has been transformative for GLP-1 receptor agonists, extending half-lives from minutes to days.
Fc Fusion
Fc fusion technology joins the peptide or protein of interest to the Fc (crystallizable fragment) region of an immunoglobulin, typically IgG1 or IgG4. The Fc domain is recognized by FcRn in endothelial cells, which diverts the fusion protein away from lysosomal degradation and recycles it back into the bloodstream. This mechanism, normally responsible for the long half-life of endogenous IgG antibodies (~21 days), can be harnessed to extend peptide half-lives into the multi-day range. Dulaglutide is a prominent example of this strategy, achieving a ~5-day half-life.
Amino Acid Modifications
Strategic amino acid substitutions can protect peptides from enzymatic cleavage without resorting to large polymer conjugations. Common strategies include replacing L-amino acids with D-amino acids at protease-sensitive positions, incorporating alpha-aminoisobutyric acid (Aib) to resist DPP-4 cleavage (as in semaglutide’s position 8 Aib substitution), N-methylation of backbone amides, cyclization to constrain the peptide conformation, and introduction of non-natural amino acids. These modifications often have a more modest effect on half-life compared to PEGylation or acylation but can be combined with other strategies for synergistic effects.
Route of Administration
The route of administration affects the apparent half-life by introducing an absorption phase that delays peak plasma concentrations. Subcutaneous injection creates a local depot from which the peptide is absorbed gradually into systemic circulation, effectively extending the apparent duration of action. Intravenous administration bypasses this absorption phase entirely, producing immediate peak concentrations but often a shorter apparent half-life. Intranasal and oral routes introduce additional variables including mucosal permeability, first-pass hepatic metabolism, and gastrointestinal degradation. See our subcutaneous injection glossary entry for more on injection pharmacokinetics.
Binding Proteins and Carrier Systems
Many peptides bind to circulating proteins beyond albumin, including specific binding proteins (e.g., IGF binding proteins for IGF-1), lipoproteins, and alpha-2-macroglobulin. These interactions can dramatically extend the circulating half-life of free peptide by creating a bound reservoir. The Drug Affinity Complex (DAC) technology used in CJC-1295 DAC takes this concept to its extreme by covalently and irreversibly binding to albumin via a reactive succinimide moiety, producing an ~8-day effective half-life from a peptide that would otherwise be cleared in minutes.
Half-Life Categories with Examples
Peptides can be grouped into five broad half-life categories, each with distinct implications for research protocol design, dosing frequency, and steady-state kinetics. The following classification is based on terminal elimination half-life under standard conditions.
These peptides are cleared from the body within minutes. They closely mimic the natural pulsatile release patterns of endogenous hormones. Ultra-short half-life peptides are typically administered via intravenous or subcutaneous injection and must be dosed frequently or delivered via continuous infusion to maintain therapeutic concentrations. Their rapid clearance makes them useful in research contexts where tight temporal control over peptide exposure is required.
| Peptide | Half-Life | Notes |
|---|---|---|
| Native GLP-1 (7-36) | ~2 minutes | Rapidly degraded by DPP-4 enzyme |
| Native GnRH | ~4 minutes | Cleaved by endopeptidases in circulation |
| Native Ghrelin | ~10 minutes | Rapid enzymatic deacylation and proteolysis |
| Oxytocin | ~3-5 minutes | Rapid hepatic and renal clearance |
| GHRH (1-44) | ~7 minutes | DPP-4 cleavage at position 2 |
| Native ACTH | ~10 minutes | Rapid proteolytic degradation |
Short half-life peptides offer a balance between rapid onset and manageable dosing frequency. Many growth hormone secretagogues fall into this category, enabling pulsatile dosing strategies that mimic the body's natural hormonal rhythms. These peptides are typically administered two to three times daily in research protocols. Their relatively brief duration of action allows researchers to study acute physiological responses while still achieving meaningful cumulative effects over the course of a study.
| Peptide | Half-Life | Notes |
|---|---|---|
| Sermorelin | ~10-20 minutes | GHRH analog, slightly more stable than native GHRH |
| GHRP-6 | ~20-30 minutes | Growth hormone secretagogue |
| GHRP-2 | ~30 minutes | More potent GHS than GHRP-6 |
| Hexarelin | ~60 minutes | Synthetic GHS hexapeptide |
| Ipamorelin | ~2 hours | Selective GH secretagogue, cleaner side-effect profile |
| BPC-157 | ~2-4 hours | Gastric pentadecapeptide; estimated from animal models |
| PT-141 (Bremelanotide) | ~2-4 hours | Melanocortin receptor agonist |
| Tesamorelin | ~26 minutes | Modified GHRH analog |
Medium half-life peptides allow once or twice daily dosing in research contexts. This category includes many therapeutically relevant peptides where molecular modifications have been applied to extend their duration of action beyond the native form. These peptides often incorporate amino acid substitutions, D-amino acid insertions, or small chemical modifications that resist enzymatic degradation without fundamentally altering the pharmacological profile. They represent a practical middle ground for research protocols requiring sustained but not ultra-prolonged exposure.
| Peptide | Half-Life | Notes |
|---|---|---|
| AOD-9604 | ~4-6 hours | Fragment of hGH (176-191) |
| Epithalon (Epitalon) | ~6-8 hours | Tetrapeptide, estimated from preclinical data |
| GHK-Cu | ~8-12 hours | Tripeptide-copper complex, tissue-dependent |
| Exenatide | ~2.4 hours (IR) | Exendin-4 based GLP-1 RA; weekly formulation extends apparent half-life |
| Thymosin Alpha-1 | ~2 hours IV; longer SC | Immunomodulatory thymic peptide |
| Liraglutide | ~13 hours | Acylated GLP-1 analog — albumin binding |
Long half-life peptides are engineered for extended duration, enabling once-weekly or even less frequent dosing. These molecules typically employ advanced modification strategies such as fatty acid acylation (promoting albumin binding), Fc fusion (leveraging FcRn recycling), or PEGylation (reducing renal clearance). The extended half-life of these peptides dramatically improves dosing convenience in long-term studies. However, the prolonged systemic exposure also means that any adverse effects will persist longer, and achieving steady state requires multiple dosing cycles.
| Peptide | Half-Life | Notes |
|---|---|---|
| CJC-1295 (no DAC) | ~30 minutes free; ~6-8 days when albumin-bound | Modified GHRH with MPA backbone |
| Semaglutide | ~7 days (168 hours) | C18 fatty diacid acylation + albumin binding + DPP-4 resistance |
| Dulaglutide | ~5 days (120 hours) | GLP-1 analog fused to IgG4 Fc fragment |
| Tirzepatide | ~5 days (120 hours) | Dual GIP/GLP-1 agonist with C20 fatty diacid |
Ultra-long half-life peptides represent the frontier of peptide engineering. These molecules can persist in systemic circulation for over a week, and in some cases, for several weeks. They achieve this extraordinary duration through strategies like DAC (Drug Affinity Complex) technology, which covalently binds the peptide to albumin in vivo, or through PEGylation with very high molecular weight PEG chains. The extended duration reduces dosing frequency to once every one to four weeks, which is valuable for chronic disease research models. However, ultra-long half-life also means extended washout periods and slower attainment of steady-state concentrations.
| Peptide | Half-Life | Notes |
|---|---|---|
| CJC-1295 DAC | ~8 days | Drug Affinity Complex for covalent albumin binding |
| PEGylated GH variants | ~10-14 days | 40 kDa PEG conjugation |
| Somapacitan | ~160 hours (~6.7 days) | Albumin-binding GH with single weekly dosing |
| Efpeglenatide | ~7-10 days | Exendin-4 Fc fusion with non-covalent PEGylation |
How Modifications Extend Half-Life: A Case Study
The evolution of GLP-1 receptor agonists provides the most instructive case study of how peptide engineering overcomes the half-life limitations of native peptides. Native GLP-1 (7-36 amide) has a half-life of approximately 2 minutes, making it pharmacologically impractical. Yet through a series of increasingly sophisticated modifications, researchers have extended the half-life by a factor of over 5,000:
Native GLP-1 — ~2 minutes
Rapidly cleaved by DPP-4 at the alanine-8 position. No modifications. Requires continuous IV infusion.
Exenatide — ~2.4 hours
Based on exendin-4 (from Gila monster venom), which naturally resists DPP-4 due to a glycine at position 2. ~70x improvement over native GLP-1. Twice-daily injection.
Liraglutide — ~13 hours
GLP-1 analog with C16 fatty acid (palmitate) acylation via a glutamate spacer, promoting albumin binding. Once-daily injection. ~390x improvement.
Semaglutide — ~168 hours (7 days)
Three key modifications: (a) Aib substitution at position 8 for DPP-4 resistance, (b) Arg34 substitution preventing a secondary cleavage, (c) C18 fatty diacid via a mini-PEG/glutamate linker for stronger albumin binding. Once-weekly injection. ~5,040x improvement.
This progression demonstrates that multiple modification strategies can be layered: enzymatic resistance (amino acid substitutions) combined with albumin binding (acylation) produces a synergistic effect on half-life extension that neither approach alone could achieve.
Steady-State Concentration
When a peptide is administered repeatedly at a fixed interval, its plasma concentration does not simply accumulate indefinitely. Instead, it approaches a steady-state where the rate of drug input (dosing) equals the rate of elimination. At steady state, the average plasma concentration remains constant from one dosing interval to the next, though it still oscillates between peak and trough values within each interval.
The time to reach steady state is governed entirely by the half-life and is independent of the dose or dosing interval. It takes approximately 4 to 5 half-lives to reach ~94-97% of the eventual steady-state concentration. This has profound practical implications:
- Ipamorelin (t½ ~2 hr): Reaches steady state within ~8-10 hours of repeated dosing.
- Liraglutide (t½ ~13 hr): Reaches steady state after ~2.5-3 days of daily dosing.
- Semaglutide (t½ ~7 days): Requires ~4-5 weeks of weekly dosing to reach full steady state.
- CJC-1295 DAC (t½ ~8 days): Requires ~5-6 weeks of weekly dosing for full steady state.
The steady-state average concentration (Css,avg) can be calculated as: Css,avg= (F × Dose) / (CL × τ), where F is bioavailability, CL is clearance, and τ is the dosing interval. For practical visualization of how concentrations build toward steady state, use our Half-Life Plotter Tool.
Washout Period
The washout period is the time required for a peptide to be effectively eliminated from the body after the last dose. By convention, a washout of 5 half-lives is considered sufficient for near-complete elimination (~96.9% cleared). Washout periods are critical for research protocol design, particularly when:
- Transitioning between different peptides in a crossover study design to avoid carryover effects.
- Establishing a clean baseline before beginning a new protocol.
- Assessing whether observed effects are reversible after discontinuation.
- Determining the appropriate timing for post-treatment biomarker measurements.
Practical washout durations based on the 5-half-life rule:
| Peptide | Half-Life | Washout (5 × t½) |
|---|---|---|
| Ipamorelin | ~2 hours | ~10 hours |
| BPC-157 | ~2-4 hours | ~10-20 hours |
| Liraglutide | ~13 hours | ~2.7 days |
| Semaglutide | ~7 days | ~5 weeks |
| CJC-1295 DAC | ~8 days | ~5.7 weeks |
For peptides that are administered at steady state, the washout period begins from the last dose and the initial plasma concentration is the steady-state trough level, not the single-dose peak. This means that effective washout from steady state may be slightly longer than 5 half-lives if the accumulation ratio is high.
Practical Implications for Protocol Design
Understanding half-life enables researchers to design protocols that achieve the desired pharmacokinetic profile. Here are the key practical considerations:
Matching Dosing to Physiology
For peptides that mimic pulsatile hormones (GH secretagogues, GnRH analogs), choose compounds with short half-lives and dose at intervals that allow trough levels to fall to near-baseline between doses. This prevents receptor desensitization and better mimics endogenous signaling patterns. Conversely, for peptides where continuous receptor occupancy is desired (GLP-1 receptor agonists for metabolic research), long-acting formulations that minimize peak-to-trough fluctuations are preferred.
Loading Dose Strategy
For long-acting peptides where waiting 4-5 weeks for steady state is impractical, a loading dose can be used to achieve target concentrations more rapidly. A loading dose is typically calculated as twice the maintenance dose and is administered at the start of the protocol. This is commonly employed with semaglutide research protocols, where a dose escalation scheme is used partly for tolerability and partly to accelerate the approach to steady state.
Timing of Biomarker Sampling
Blood samples for pharmacodynamic endpoints should be collected at consistent time points relative to dosing. Trough levels (just before the next dose) are the most reproducible and are standard for therapeutic drug monitoring. Peak levels, while useful for safety assessments, are more variable and depend on absorption kinetics. For short-acting peptides like ipamorelin, the sampling window is narrow and timing is critical.
Reconstitution and Stability Considerations
A peptide’s in-vivo half-life is distinct from its chemical stability in solution after reconstitution. Many peptides with long in-vivo half-lives (achieved through albumin binding or other mechanisms) may still have limited stability in bacteriostatic water at room temperature. Always consult the specific storage and handling guidelines for each compound. Visit our storage and handling guide and reconstitution guide for detailed protocols.
Complete Peptide Half-Life Reference Table
The following table summarizes the half-lives, categories, and key structural modifications for commonly researched peptides. All values represent terminal elimination half-life under standard conditions unless otherwise noted. Values are approximate and may vary based on species, route of administration, and individual metabolic factors.
| Peptide | Half-Life |
|---|---|
| Native GLP-1 | ~2 min |
| Native GnRH | ~4 min |
| Oxytocin | ~3-5 min |
| GHRH (1-44) | ~7 min |
| Native Ghrelin | ~10 min |
| Sermorelin | ~10-20 min |
| GHRP-6 | ~20-30 min |
| GHRP-2 | ~30 min |
| Tesamorelin | ~26 min |
| Hexarelin | ~60 min |
| Ipamorelin | ~2 hr |
| BPC-157 | ~2-4 hr |
| PT-141 | ~2-4 hr |
| AOD-9604 | ~4-6 hr |
| Exenatide (IR) | ~2.4 hr |
| Liraglutide | ~13 hr |
| CJC-1295 (no DAC) | ~30 min free |
| Dulaglutide | ~5 days |
| Tirzepatide | ~5 days |
| Semaglutide | ~7 days |
| CJC-1295 DAC | ~8 days |
| Somapacitan | ~6.7 days |
Frequently Asked Questions
What is the half-life of a peptide?
The half-life of a peptide is the time required for its plasma concentration to decrease by 50% after administration. It is a fundamental pharmacokinetic parameter that determines how long a peptide remains active in the body and directly influences dosing frequency, steady-state concentrations, and washout periods in research protocols.
Why do native peptides have such short half-lives?
Native peptides evolved for rapid, pulsatile signaling and are intentionally short-lived. They are rapidly degraded by ubiquitous proteolytic enzymes (such as DPP-4, NEP, and ACE), cleared by the kidneys due to their small molecular weight (typically under 5 kDa), and lack structural features that would protect them from enzymatic attack. This rapid turnover allows the body to precisely control signaling intensity.
How does PEGylation extend peptide half-life?
PEGylation attaches polyethylene glycol (PEG) chains to a peptide, increasing its hydrodynamic radius and molecular weight. This reduces renal filtration (kidneys filter molecules below ~60 kDa), shields the peptide from proteolytic enzymes by steric hindrance, and decreases immunogenicity. A 40 kDa PEG chain can extend half-life from minutes to days, depending on the native peptide and PEG attachment site.
What is the difference between half-life and duration of action?
Half-life measures how quickly the drug's plasma concentration declines, while duration of action describes how long the drug produces its pharmacological effect. They are related but distinct: a peptide may have biological effects that persist beyond the point where plasma concentrations have dropped below measurable levels, especially if the peptide triggers downstream signaling cascades or has high receptor affinity with slow dissociation rates.
How many half-lives until a peptide is fully cleared?
A peptide is considered effectively eliminated after approximately 5 half-lives, at which point ~96.875% of the original dose has been cleared. After 4 half-lives, ~93.75% is cleared. This principle is critical for determining washout periods between different research protocols and for calculating the time to reach steady-state concentrations during repeated dosing.
What is steady-state concentration and how is it related to half-life?
Steady-state concentration occurs when the rate of drug administration equals the rate of elimination, resulting in stable average plasma levels. It is reached after approximately 4-5 half-lives of repeated dosing at consistent intervals. For example, a peptide with a 7-day half-life would reach steady state after approximately 4-5 weeks of weekly dosing.
Does route of administration affect peptide half-life?
The route of administration significantly affects apparent half-life. Intravenous injection produces the highest peak concentration but often the shortest apparent half-life due to immediate systemic exposure. Subcutaneous injection creates a depot effect at the injection site, producing a slower absorption phase that can extend the apparent duration of action. Intranasal and oral routes introduce additional absorption barriers that affect bioavailability but may not extend true elimination half-life.
How does fatty acid acylation extend half-life (as in semaglutide)?
Fatty acid acylation attaches a lipophilic fatty acid chain (such as a C18 fatty diacid in semaglutide) to the peptide. This fatty acid chain binds reversibly to serum albumin, which has a half-life of ~19 days. By 'hitchhiking' on albumin, the peptide avoids renal filtration, is shielded from proteolytic enzymes, and is recycled via the FcRn pathway. This can extend half-life from minutes to an entire week.
Research Disclaimer
All information presented on this page is intended for educational and informational purposes only, specifically for qualified researchers and academic institutions conducting in vitro research. Peptide half-life values are approximate and derived from published pharmacokinetic studies; actual values may vary based on species, formulation, route of administration, and individual metabolic factors. These compounds are sold exclusively for in vitro research use. Not for human consumption, diagnostic, or therapeutic use. Volta Peptides does not provide medical advice. Consult the primary literature and relevant regulatory guidelines for your jurisdiction before designing any research protocol.
Browse Catalog
Explore our full range of high-purity research peptides.
View catalogResearch Tools
Half-life plotter, bioavailability calculator, and more.
Explore toolsLearning Center
Guides on reconstitution, storage, and peptide science.
Start learning